Synthetic Controls for Implementation Science: Opportunities for HIV Program Evaluation Using Routinely Collected Data.

Autor: Wallach S; Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, 10032, USA. sara.wallach@columbia.edu.; Mailman School of Public Health, ICAP at Columbia University, 722 West 168th Street, New York, 10032, USA. sara.wallach@columbia.edu., Saito S; Mailman School of Public Health, ICAP at Columbia University, 722 West 168th Street, New York, 10032, USA., Nuwagaba-Biribonwoha H; Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, 10032, USA.; Mailman School of Public Health, ICAP at Columbia University, 722 West 168th Street, New York, 10032, USA., Dube L; Government of the Kingdom of Eswatini, Ministry of Health, Mbabane, Eswatini., Lamb MR; Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, 10032, USA.; Mailman School of Public Health, ICAP at Columbia University, 722 West 168th Street, New York, 10032, USA.

Publikováno v: Current HIV/AIDS reports [Curr HIV/AIDS Rep] 2024 Jun; Vol. 21 (3), pp. 140-151. Date of Electronic Publication: 2024 Mar 13.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effect and cost-effectiveness of human-centred design-based approaches to increase adolescent uptake of modern contraceptives in Nigeria, Ethiopia and Tanzania: Population-based, quasi-experimental studies.

Autor: Krug C; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom., Neuman M; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.; MRC International Statistics and Epidemiology Group, London, United Kingdom., Rosen JE; Avenir Health, Washington, DC, United States of America., Weinberger M; Avenir Health, Washington, DC, United States of America., Wallach S; Itad, Hove, United Kingdom., Lagaay M; Itad, Hove, United Kingdom., Punton M; Itad, Hove, United Kingdom., Prakash A; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom., Nsanya MK; Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania., Ayieko P; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.; MRC International Statistics and Epidemiology Group, London, United Kingdom.; Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania., Kapiga S; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.; Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania., Ajayi YP; Binomial Optimus Limited, Abuja, Nigeria., Crawford EE; Binomial Optimus Limited, Abuja, Nigeria., Tenaw E; MMA Development Consultancy, Addis Ababa, Ethiopia., Mussa M; MMA Development Consultancy, Addis Ababa, Ethiopia., Shrestha SK; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom., Bottomley C; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.; MRC International Statistics and Epidemiology Group, London, United Kingdom., Hargreaves JR; Department of Public Health, Environment and Society Research, London School of Hygiene and Tropical Medicine, London, United Kingdom., Doyle AM; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.; MRC International Statistics and Epidemiology Group, London, United Kingdom.

Publikováno v: PLOS global public health [PLOS Glob Public Health] 2023 Oct 18; Vol. 3 (10), pp. e0002347. Date of Electronic Publication: 2023 Oct 18 (Print Publication: 2023).

P79 Real-world outcomes of disease-modifying treatment for patients with spinal muscular atrophy: findings from a global retrospective chart review

Autor: Dabbous, O., LaMarca, N., Toro, W., Wallach, S., Mumneh, N., Aassi, M., O'Brien, E., Baranello, G., Reyna, S.

Publikováno v: In Neuromuscular Disorders October 2023 33 Supplement 1:S136-S136

Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment.

Autor: McGrattan KE; University of Minnesota, Minneapolis, MN, USA., Shell RD; Nationwide Children's Hospital, Columbus, OH, USA.; Department of Pediatrics, The Ohio State University, Columbus, OH, USA., Hurst-Davis R; Primary Children's Hospital, Salt Lake City, UT, USA., Young SD; Stanford University School of Medicine, Stanford, CA, USA., O'Brien E; Novartis, Dublin, Ireland., Lavrov A; Novartis Gene Therapies, Inc., Cambridge, UK., Wallach S; Novartis Gene Therapies, Inc., Bannockburn, IL, USA., LaMarca N; Novartis Gene Therapies, Inc., Bannockburn, IL, USA., Reyna SP; Novartis Gene Therapies, Inc., Bannockburn, IL, USA., Darras BT; Department of Neurology, Boston Children's Hospital, Boston, MA, USA.

Publikováno v: Journal of neuromuscular diseases [J Neuromuscul Dis] 2023; Vol. 10 (4), pp. 531-540.